218 related articles for article (PubMed ID: 29976041)
21. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
Lazarou IN; Guerne PA
J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
[TBL] [Abstract][Full Text] [Related]
22. Rituximab therapy in necrotizing autoimmune myopathy associated with anti-SRP antibody: A clinical case review.
Nóvoa Medina FJ; Gutiérrez Martínez J; González González Y; Romero Díaz B; Machín García S; Rosas Romero A
Reumatol Clin (Engl Ed); 2018; 14(6):379-381. PubMed ID: 28389200
[TBL] [Abstract][Full Text] [Related]
23. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
Reis J; Aguiar F; Brito I
Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
[TBL] [Abstract][Full Text] [Related]
24. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.
Rios Fernández R; Callejas Rubio JL; Sánchez Cano D; Sáez Moreno JA; Ortego Centeno N
Clin Exp Rheumatol; 2009; 27(6):1009-16. PubMed ID: 20149324
[TBL] [Abstract][Full Text] [Related]
25. Biologic therapy in the idiopathic inflammatory myopathies.
Khoo T; Limaye V
Rheumatol Int; 2020 Feb; 40(2):191-205. PubMed ID: 31680207
[TBL] [Abstract][Full Text] [Related]
26. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.
Valiyil R; Casciola-Rosen L; Hong G; Mammen A; Christopher-Stine L
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1328-34. PubMed ID: 20506493
[TBL] [Abstract][Full Text] [Related]
27. Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study.
Conticini E; d'Alessandro M; Grazzini S; Rizzo C; Fornaro M; Cameli P; Bennett D; Abbruzzese A; Camarda F; Lopalco G; Bergantini L; Falsetti P; Bargagli E; Iannone F; Guggino G; Chinoy H; Cantarini L; Frediani B
Clin Exp Rheumatol; 2023 Mar; 41(2):285-290. PubMed ID: 36861742
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis.
Giannini M; Fiorella ML; Tampoia M; Girolamo F; Fornaro M; Amati A; Lia A; Abbracciavento L; D'Abbicco D; Iannone F
Rheumatology (Oxford); 2021 Mar; 60(3):1234-1242. PubMed ID: 32911543
[TBL] [Abstract][Full Text] [Related]
29. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
30. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series.
Basnayake C; Cash K; Blumbergs P; Limaye V
Clin Rheumatol; 2015 Feb; 34(2):371-7. PubMed ID: 24337692
[TBL] [Abstract][Full Text] [Related]
31. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
[TBL] [Abstract][Full Text] [Related]
32. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.
Wilkes MR; Sereika SM; Fertig N; Lucas MR; Oddis CV
Arthritis Rheum; 2005 Aug; 52(8):2439-46. PubMed ID: 16052580
[TBL] [Abstract][Full Text] [Related]
33. Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy.
Landon-Cardinal O; Allenbach Y; Soulages A; Rigolet A; Hervier B; Champtiaux N; Monzani Q; Solé G; Benveniste O
J Rheumatol; 2019 Jun; 46(6):623-627. PubMed ID: 30554155
[TBL] [Abstract][Full Text] [Related]
34. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of rituximab in refractory neuromyelitis optica.
Collongues N; Brassat D; Maillart E; Labauge P; Ouallet JC; Carra-Dalliere C; Moreau T; Bourre B; Papeix C; Brochet B; Audoin B; Vukusic S; de Seze J; Marignier R;
Mult Scler; 2016 Jun; 22(7):955-9. PubMed ID: 26362900
[TBL] [Abstract][Full Text] [Related]
36. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
Chartrand S; Swigris JJ; Peykova L; Fischer A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
38. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.
Marie I; Dominique S; Janvresse A; Levesque H; Menard JF
Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877
[TBL] [Abstract][Full Text] [Related]
39. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
Aggarwal R; Oddis CV; Goudeau D; Koontz D; Qi Z; Reed AM; Ascherman DP; Levesque MC
Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
[TBL] [Abstract][Full Text] [Related]
40. Biologics for idiopathic inflammatory myopathies.
Moghadam-Kia S; Aggarwal R; Oddis CV
Curr Opin Rheumatol; 2017 Nov; 29(6):645-651. PubMed ID: 28817464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
